Corcept <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Phase 3 Results for Relacorilant in Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated has announced new data from its pivotal Phase 3 ROSELLA trial evaluating relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The results, presented at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting, demonstrated a progression-free survival benefit, particularly in patients whose disease progressed while on or after taking a PARP inhibitor. Additionally, Corcept reported the expansion of its Phase 2 BELLA trial to three study arms, which will examine the efficacy and safety of relacorilant plus nab-paclitaxel and bevacizumab in platinum-resistant and platinum-sensitive ovarian cancer, as well as relacorilant plus nab-paclitaxel in endometrial cancer. Initial results from the BELLA trial are expected in late 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20251019109551) on October 19, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。